IQVIA released the China PD-(L)1 market dynamics report for the first half of 2022

China PD-(L)1 Market Overview

Recently, IQVIA's "China PD-(L)1 Drug Market Dynamics Report 2022H1" was officially released
.

As of the time of the report, 15 PD-(L)1 products have been approved for marketing, and another 4 products are in the process of NDA new drug market applications, 3 of which are expected to be approved by the end of this year and early next year
.

In China, since the approval of Odivo (O drug) and Koreda (K drug) in 2018, as of the time of this report, 15 PD-(L)1 products have been listed, of which 11 PD-1 and 4 PD-L1 involve 13 tumor species and related pan-tumor species
.

From the market performance of 12 cities monitored by IQVIA OD™ database, the use rate of PD-(L)1 in first-tier cities is higher than that in second-tier cities, and domestic brands account for a relatively large proportion, and in the first half of 2022, domestic brands account for 76.

1) Based on the number of cases in the OD™ database, among all PD-(L)1 brands, the top 3 of the overall patient share in the first half of 2022 are domestic brands, with Xinda's Daboshu in the first place, followed by Baizean, Erica and the top 3 with concentrated shares, accounting for more than 60% of the patient share
.

2) Among all PD-(L)1 drug-treated tumors, based on the number of cases in the OD™ database, non-small cell lung cancer is still the main tumor field of immune governance, accounting for 31.

Source: IQVIA Tumor Dynamic Information Database "China PD-(L)1 Drug Market Dynamics Report 2022H1"

OD™ Database is IQVIA's global unified platform combined with China's professional tumor database
of tumor epidemiology.